Buprenorphine Induction Protocol — Speaker Companion

⏱️ Duration: 45 minutes 👥 Audience: PMHNPs, addiction psychiatry fellows 📊 Slides: 18 🎯 Level: Intermediate
Target Maintenance Dose:
16-24 mg/day
COWS Induction Threshold:
8-12 (moderate withdrawal)
Key Board Trap:
Fentanyl + standard induction = high precipitated withdrawal risk
X-Waiver Status:
Eliminated January 2023
Slide 01

Title Slide

2 min

Speaker Notes

  • Welcome audience, establish credibility
  • Preview disclosure about off-label medications
  • Set expectation: interactive cases ahead
  • Emphasize practical, office-based applicability
💡 Tip: Make eye contact with back row during welcome — establishes presence in larger rooms
→ Transition: "Today we'll cover a protocol that has transformed office-based addiction treatment..."

Anticipated Questions

Q1: "Is this presentation accredited for CME?"

A: Check with your state board for credit eligibility. PCSS modules at pcssNOW.org offer free CME.

Easy 1 min
Q2: "Will slides be available after?"

A: Yes, interactive HTML version will be shared via email and posted in THE CODEX.

Easy 1 min
Slide 02

Learning Objectives

2 min

Speaker Notes

  • Read each objective clearly
  • Pause briefly between objectives
  • Highlight "two critical decisions" framework (preview of summary)
💡 Tip: Use hand gesture to indicate "four quadrants" as you present objectives

Anticipated Questions

Q1: "Will we cover methadone conversion?"

A: Briefly in context of induction timing. Full methadone-to-buprenorphine transition is a separate session. Key point: require 36-72 hours off methadone before buprenorphine induction.

Medium 2 min
Slide 03

Why This Matters

3 min

Speaker Notes

  • Emphasize accessibility — X-waiver elimination was transformative
  • Name-check PMHNPs as primary providers (audience relevance)
  • Pause on "critical gap" — this is the pivot to modern fentanyl era
⚠️ Watch for: Audience assuming standard induction still works for all patients
🎯 Key Point: The fentanyl era has changed everything about induction timing

Anticipated Questions

Q1: "What percentage of street opioids now contain fentanyl?"

A: Varies by region, but DEA data shows 40-60% of seized pills contain fentanyl, and heroin supply is heavily adulterated. Assume fentanyl exposure unless proven otherwise.

Medium 2 min
Q2: "Do we still need DATA 2000 training?"

A: No. As of January 2023, any DEA-licensed prescriber can prescribe buprenorphine for OUD. Training is still valuable but no longer legally required.

Easy 1 min
Slide 04

Core Principles

4 min

Speaker Notes

  • Walk through each principle — emphasize pharmacology
  • Principle 1: Explain "high receptor binding affinity" concept simply
  • Principle 3: "This is the game-changer for fentanyl"
  • Principle 4: Underdosing is the hidden epidemic in OUD treatment
💡 Tip: Use analogy: buprenorphine is like a "bully" that pushes other opioids off receptors — timing matters

Anticipated Questions

Q1: "Why is underdosing so common?"

A: Historic stigma around "replacing one drug with another," fear of diversion, lack of familiarity with effective dosing. 8 mg is often subtherapeutic — evidence shows better retention at 16-24 mg.

Medium 2 min
Q2: "Is there a ceiling effect with buprenorphine?"

A: Yes — partial agonist with ceiling effect around 32 mg. Beyond this, minimal additional effect but increased side effects. 16-24 mg is the evidence-based sweet spot.

Medium 2 min
Slide 05

Pre-Induction Checklist

3 min

Speaker Notes

  • Don't just read the list — emphasize the critical decision
  • "Current opioid type" is where you choose your path
  • UDS is essential — but don't delay treatment waiting for results
⚠️ Watch for: Trainees wanting to complete ALL items before starting — naloxone and consent can happen Day 1
→ Transition: "Based on your assessment, you'll choose one of three induction methods..."

Anticipated Questions

Q1: "Can we start buprenorphine same-day as initial visit?"

A: Yes — same-day initiation is increasingly standard. Don't create artificial barriers. Complete UDS and consent, then induce if patient is in appropriate withdrawal.

Easy 1 min
Q2: "What if pregnancy test is positive?"

A: Proceed with buprenorphine — it's the standard of care in pregnancy. Use monoproduct (Subutex) without naloxone. Coordinate with OB for NAS monitoring.

Medium 2 min
Slide 06

Induction Method Comparison

4 min

Speaker Notes

  • Walk through table row by row
  • Highlight the "requires withdrawal" row — this is the differentiator
  • Emphasize: low-dose is becoming the default for unknown opioid source
💡 Tip: Point to the "risk" column — visual contrast between moderate and very low
🎯 Key Point: When in doubt about opioid type, choose low-dose induction

Anticipated Questions

Q1: "Is low-dose induction evidence-based or experimental?"

A: Evidence-based. Hammig 2016, Ahmed 2021, and De Aquino 2023 have established protocols. SAMHSA TIP 63 (2024) includes microdosing guidance.

Medium 2 min
Q2: "Does insurance cover multiple early visits for low-dose?"

A: Generally yes — bill as OUD treatment visits. Telehealth can reduce burden. The 7-day protocol can be adapted to 3-4 visits with phone checks.

Medium 2 min
Slide 07

Case 1 — Maria

5 min

Speaker Notes

  • Read case slowly, especially the quote
  • Pause for audience to formulate answer before reveal
  • Click reveal button AFTER discussion
  • Emphasize: "This is the classic scenario for standard induction"
⚠️ Watch for: Someone suggesting "let's wait longer" — COWS 11 is perfect, don't delay
🎯 Key Point: Heroin + moderate withdrawal + motivation = standard induction

Anticipated Questions

Q1: "What if Maria had used fentanyl instead of heroin?"

A: COWS 11 might still be too early with fentanyl due to tissue depot. Would strongly consider low-dose microdosing instead, or wait 48-72 hours with close monitoring.

Hard 3 min
Q2: "Should we give 2 mg or 4 mg to start?"

A: Conservative: 2 mg, reassess at 1 hour. Confident: 4 mg. With COWS 11 and clear heroin use, 4 mg is reasonable. Always reassess at 1-2 hours.

Medium 2 min
Slide 08

Standard Induction Protocol

3 min

Speaker Notes

  • Walk through days 1-7
  • Emphasize the 1-2 hour reassessment — this is critical
  • Day 3-7: titrate based on patient report, not protocol alone
💡 Tip: Mention that patients often undertreport cravings — ask specifically about "using dreams" or situational triggers
→ Transition: "But how do we know when it's safe to start? This is where COWS comes in..."

Anticipated Questions

Q1: "What if patient vomits the dose?"

A: Sublingual absorption is rapid. If vomiting occurs >10 minutes after placement, assume absorption occurred. If immediate, can cautiously re-dose 50% of original amount.

Medium 2 min
Q2: "Can we go higher than 8 mg on day 1?"

A: Not recommended for standard induction. Risk of precipitated withdrawal if COWS was overestimated. Better to be conservative and escalate on day 2.

Medium 2 min
Slide 09

COWS Scoring

4 min

Speaker Notes

  • Walk through each score range
  • Highlight the visual color coding on screen
  • Emphasize: "8-12 is the sweet spot"
⚠️ Watch for: Someone suggesting early induction at COWS 5-7 — emphasize waiting
🎯 Key Point: Precipitated withdrawal destroys trust — when in doubt, wait

Anticipated Questions

Q1: "Is there a validated COWS self-assessment for home induction?"

A: Yes — PCSS and SAMHSA both have patient-facing COWS guides. Accuracy is generally good in motivated patients. Provide written instructions with phone backup.

Easy 1 min
Q2: "What if patient exaggerates symptoms to get medication?"

A: Use objective signs (vital signs, pupil size, piloerection) alongside subjective report. But remember: we treat based on assessment, not suspicion. A few extra hours of waiting won't harm anyone.

Hard 3 min
Slide 10

Low-Dose Microdosing

5 min

Speaker Notes

  • Emphasize: "This is the game-changer for fentanyl era"
  • Walk through day-by-day progression
  • Note that patient continues using during days 1-4
  • Day 5: full transition point
💡 Tip: Use hand gestures to show the "ramp up" of buprenorphine and "ramp down" of other opioids
🎯 Key Point: No withdrawal window needed — this is the revolution

Anticipated Questions

Q1: "How do patients get 0.5 mg doses?"

A: 2 mg films can be cut into quarters. Some pharmacies compound liquid buprenorphine. Butrans patches (5-20 mcg/hr) are an alternative for days 1-3.

Medium 2 min
Q2: "Isn't it dangerous to have patients using while starting buprenorphine?"

A: With microdosing, buprenorphine levels are sub-threshold until day 5-6, so no displacement occurs. By then, patient has built up partial agonist protection.

Hard 3 min
Slide 11

Case 2 — James

5 min

Speaker Notes

  • Read the quote — James's trauma is real
  • Pause for audience to process
  • This case requires empathy + clinical precision
⚠️ Watch for: Someone suggesting "let's try standard again, maybe he'll tolerate it" — no, his trauma is valid
🎯 Key Point: Validate the trauma, then offer the solution: microdosing

Anticipated Questions

Q1: "What if James isn't compliant with multiple visits?"

A: Consider Butrans patch (5-20 mcg/hr) days 1-3, then single visit to switch to sublingual. Or use phone/telehealth check-ins for days 3-5.

Medium 2 min
Q2: "Can we use this protocol for all patients?"

A: Yes — it's becoming default for many practices. Only downside is longer timeline. Advantages: no precipitated withdrawal, more flexible, patient-centered.

Medium 2 min
Slide 12

Stabilization & Maintenance

3 min

Speaker Notes

  • Emphasize 16-24 mg/day — many underdose
  • Once daily preferred for adherence
  • Split dosing (BID) if evening cravings persist
⚠️ Watch for: Trainees stopping at 8 mg because "patient seems stable" — ask about cravings, not just withdrawal
🎯 Key Point: Cravings suppressed = better retention. Don't undertreat.

Anticipated Questions

Q1: "How long should patients stay on buprenorphine?"

A: Indefinite is appropriate for most. OUD is a chronic condition. Taper only when patient requests and has stable recovery supports. Most relapses occur during/after taper.

Hard 3 min
Q2: "What about take-home doses vs daily witnessed?"

A: Office-based prescribing allows take-home. Start with 1 week supply, expand as stable. Daily witnessed dosing is methadone clinic model, not required for buprenorphine.

Medium 2 min
Slide 13

Pitfalls & Cautions

4 min

Speaker Notes

  • Walk through each pitfall
  • Precipitated withdrawal — emphasize it's preventable
  • Underdosing — "This is the hidden epidemic in OUD treatment"
  • Benzos — not a contraindication, but requires caution
💡 Tip: Use personal anecdote if available: "I once had a patient..."

Anticipated Questions

Q1: "How do you manage a patient on benzos?"

A: Continue both if medically necessary. Increase monitoring frequency. Consider prescribing naloxone to household members. Coordinate with prescriber of benzos. Goal is risk reduction, not forced taper of either medication.

Hard 3 min
Q2: "What if we suspect diversion?"

A: Remember: most diversion is self-treatment by people without access. Approach with harm reduction mindset. Consider observed dosing, shorter intervals, but don't abruptly discontinue — this drives people to fentanyl.

Hard 3 min
Slide 14

Safety Monitoring

3 min

Speaker Notes

  • UDS schedule: baseline, weekly x4, then monthly
  • PDMP checks — essential in early stabilization
  • Telehealth — emphasize as retention tool
🎯 Key Point: Telehealth isn't "less than" — it's evidence-based for OUD

Anticipated Questions

Q1: "What if UDS shows continued fentanyl use?"

A: Expected in early stabilization. Discuss without judgment. Assess if cravings are suppressed (dose adequacy). Continue treatment — OUD recovery is not binary. Use as engagement tool, not termination reason.

Medium 2 min
Slide 15

Special Populations

3 min

Speaker Notes

  • Pregnancy: buprenorphine is standard of care
  • Hepatic disease: monitor, but buprenorphine is generally safe
  • QTc: NOT a concern (unlike methadone)
  • Diversion: harm reduction approach

Anticipated Questions

Q1: "Can buprenorphine be used in adolescent OUD?"

A: Yes, FDA approved age 16+. Same protocols apply. Family involvement is crucial. Consider higher intensity psychosocial support.

Medium 2 min
Q2: "What about severe liver disease (Child-Pugh C)?"

A: Consider methadone instead, which doesn't rely on hepatic metabolism to the same degree. If buprenorphine is only option, use with caution and close monitoring.

Hard 2 min
Slide 16

Practical Pearls

3 min

Speaker Notes

  • Film vs tablet — bioavailability difference matters
  • Buccal placement — option for sublingual challenges
  • Telehealth — "This changed everything during COVID"
  • Start where patient is — don't create barriers
→ Transition: "Let's bring this all together..."

Anticipated Questions

Q1: "What if patient can't afford Suboxone?"

A: Check manufacturer patient assistance programs. Generic buprenorphine/naloxone is much cheaper than brand. Some states have OUD medication assistance programs. Medicaid covers in all states.

Medium 2 min
Slide 17

Summary: Bottom Line

3 min

Speaker Notes

  • Review two critical decisions
  • Safety priorities
  • Implementation access
  • Retention strategies
🎯 Key Point: You have the tools — use them. Low-dose microdosing + effective maintenance dosing = lives saved.

Anticipated Questions

Q1: "What's the first step to implement this in my practice?"

A: Start with one patient. Use standard induction for clear short-acting opioid use; use low-dose for any fentanyl concern. Get comfortable with the process, then expand. PCSS mentorship is available.

Easy 2 min
Slide 18

References

2 min

Speaker Notes

  • SAMHSA TIP 63 is the gold standard reference
  • ASAM guideline for comprehensive overview
  • PCSS modules for training
💡 Tip: End with availability for questions and contact information

Anticipated Questions

Q1: "How do I get started with PCSS mentorship?"

A: Visit pcssNOW.org — free registration, free CME, mentorship pairing available. Also SAMHSA has a provider locator for experienced prescribers willing to mentor.

Easy 1 min

Session Timing Guide

0:00–0:05 Title + Learning Objectives
0:05–0:12 Context + Principles + Assessment
0:12–0:22 Method Comparison + Cases (1 & 2)
0:22–0:35 Protocols + COWS + Microdosing
0:35–0:42 Stabilization + Pitfalls + Monitoring
0:42–0:45 Pearls + Summary + References